Prognostic factors and antibiotics in Vibrio vulnificus septicemia

Jien Wei Liu, Ing Kit Lee, Hung Jen Tang, Wen Chien Ko, Hsin Chun Lee, Yung-Ching Liu, Po Ren Hsueh, Yin Ching Chuang

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Immunocompromised patients with Vibrio vulnificus septicemia are at high risk for fatality. When a hemorrhagic bullous necrotic cutaneous lesion (HBNCL) and decreased blood pressure develop, approximately 50% of V vulnificus septicemic patients die within 48 hours. This study aimed to evaluate the risk factor(s) for fatality among patients with V vulnificus septicemia, emphasizing the role of prescribed antimicrobial agents in general and the therapeutic efficacy of the combination of a third-generation cephalosporin and tetracycline or its analogue in particular. Methods: Patients with the diagnosis of V vulnificus infection admitted to 5 large medical centers in Taiwan between 1995 and 2003 were included in this retrospective study. Patients were divided into 2 groups: those with HBNCLs and those without HBNCLs. Patients were further divided into subgoups without fatalities (fatal subgroup) and those without fatalities (nonfatal subgroup). Results: A total of 93 patients participated in the study. In group 1, the fatal subgroup had higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (P=.006) and a higher proportion of shock at arrival at the medical center (P=.015) than the nonfatal subgroup. In group 2, the effect of a first- or secondgeneration cephalosporin plus an aminoglycoside was negative (P = .01) and that of combined third-generation cephalosporin and tetracycline or its analogue was positive (P

Original languageEnglish
Pages (from-to)2117-2123
Number of pages7
JournalArchives of Internal Medicine
Volume166
Issue number19
DOIs
Publication statusPublished - Oct 23 2006
Externally publishedYes

Fingerprint

Vibrio vulnificus
Sepsis
Anti-Bacterial Agents
Cephalosporins
Tetracycline
APACHE
Immunocompromised Host
Aminoglycosides
Anti-Infective Agents
Taiwan
Shock
Retrospective Studies
Blood Pressure
Skin
Infection

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Liu, J. W., Lee, I. K., Tang, H. J., Ko, W. C., Lee, H. C., Liu, Y-C., ... Chuang, Y. C. (2006). Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Archives of Internal Medicine, 166(19), 2117-2123. https://doi.org/10.1001/archinte.166.19.2117

Prognostic factors and antibiotics in Vibrio vulnificus septicemia. / Liu, Jien Wei; Lee, Ing Kit; Tang, Hung Jen; Ko, Wen Chien; Lee, Hsin Chun; Liu, Yung-Ching; Hsueh, Po Ren; Chuang, Yin Ching.

In: Archives of Internal Medicine, Vol. 166, No. 19, 23.10.2006, p. 2117-2123.

Research output: Contribution to journalArticle

Liu, JW, Lee, IK, Tang, HJ, Ko, WC, Lee, HC, Liu, Y-C, Hsueh, PR & Chuang, YC 2006, 'Prognostic factors and antibiotics in Vibrio vulnificus septicemia', Archives of Internal Medicine, vol. 166, no. 19, pp. 2117-2123. https://doi.org/10.1001/archinte.166.19.2117
Liu, Jien Wei ; Lee, Ing Kit ; Tang, Hung Jen ; Ko, Wen Chien ; Lee, Hsin Chun ; Liu, Yung-Ching ; Hsueh, Po Ren ; Chuang, Yin Ching. / Prognostic factors and antibiotics in Vibrio vulnificus septicemia. In: Archives of Internal Medicine. 2006 ; Vol. 166, No. 19. pp. 2117-2123.
@article{d1287face0d843589af3d63dd5b52bfe,
title = "Prognostic factors and antibiotics in Vibrio vulnificus septicemia",
abstract = "Background: Immunocompromised patients with Vibrio vulnificus septicemia are at high risk for fatality. When a hemorrhagic bullous necrotic cutaneous lesion (HBNCL) and decreased blood pressure develop, approximately 50{\%} of V vulnificus septicemic patients die within 48 hours. This study aimed to evaluate the risk factor(s) for fatality among patients with V vulnificus septicemia, emphasizing the role of prescribed antimicrobial agents in general and the therapeutic efficacy of the combination of a third-generation cephalosporin and tetracycline or its analogue in particular. Methods: Patients with the diagnosis of V vulnificus infection admitted to 5 large medical centers in Taiwan between 1995 and 2003 were included in this retrospective study. Patients were divided into 2 groups: those with HBNCLs and those without HBNCLs. Patients were further divided into subgoups without fatalities (fatal subgroup) and those without fatalities (nonfatal subgroup). Results: A total of 93 patients participated in the study. In group 1, the fatal subgroup had higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (P=.006) and a higher proportion of shock at arrival at the medical center (P=.015) than the nonfatal subgroup. In group 2, the effect of a first- or secondgeneration cephalosporin plus an aminoglycoside was negative (P = .01) and that of combined third-generation cephalosporin and tetracycline or its analogue was positive (P",
author = "Liu, {Jien Wei} and Lee, {Ing Kit} and Tang, {Hung Jen} and Ko, {Wen Chien} and Lee, {Hsin Chun} and Yung-Ching Liu and Hsueh, {Po Ren} and Chuang, {Yin Ching}",
year = "2006",
month = "10",
day = "23",
doi = "10.1001/archinte.166.19.2117",
language = "English",
volume = "166",
pages = "2117--2123",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "19",

}

TY - JOUR

T1 - Prognostic factors and antibiotics in Vibrio vulnificus septicemia

AU - Liu, Jien Wei

AU - Lee, Ing Kit

AU - Tang, Hung Jen

AU - Ko, Wen Chien

AU - Lee, Hsin Chun

AU - Liu, Yung-Ching

AU - Hsueh, Po Ren

AU - Chuang, Yin Ching

PY - 2006/10/23

Y1 - 2006/10/23

N2 - Background: Immunocompromised patients with Vibrio vulnificus septicemia are at high risk for fatality. When a hemorrhagic bullous necrotic cutaneous lesion (HBNCL) and decreased blood pressure develop, approximately 50% of V vulnificus septicemic patients die within 48 hours. This study aimed to evaluate the risk factor(s) for fatality among patients with V vulnificus septicemia, emphasizing the role of prescribed antimicrobial agents in general and the therapeutic efficacy of the combination of a third-generation cephalosporin and tetracycline or its analogue in particular. Methods: Patients with the diagnosis of V vulnificus infection admitted to 5 large medical centers in Taiwan between 1995 and 2003 were included in this retrospective study. Patients were divided into 2 groups: those with HBNCLs and those without HBNCLs. Patients were further divided into subgoups without fatalities (fatal subgroup) and those without fatalities (nonfatal subgroup). Results: A total of 93 patients participated in the study. In group 1, the fatal subgroup had higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (P=.006) and a higher proportion of shock at arrival at the medical center (P=.015) than the nonfatal subgroup. In group 2, the effect of a first- or secondgeneration cephalosporin plus an aminoglycoside was negative (P = .01) and that of combined third-generation cephalosporin and tetracycline or its analogue was positive (P

AB - Background: Immunocompromised patients with Vibrio vulnificus septicemia are at high risk for fatality. When a hemorrhagic bullous necrotic cutaneous lesion (HBNCL) and decreased blood pressure develop, approximately 50% of V vulnificus septicemic patients die within 48 hours. This study aimed to evaluate the risk factor(s) for fatality among patients with V vulnificus septicemia, emphasizing the role of prescribed antimicrobial agents in general and the therapeutic efficacy of the combination of a third-generation cephalosporin and tetracycline or its analogue in particular. Methods: Patients with the diagnosis of V vulnificus infection admitted to 5 large medical centers in Taiwan between 1995 and 2003 were included in this retrospective study. Patients were divided into 2 groups: those with HBNCLs and those without HBNCLs. Patients were further divided into subgoups without fatalities (fatal subgroup) and those without fatalities (nonfatal subgroup). Results: A total of 93 patients participated in the study. In group 1, the fatal subgroup had higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (P=.006) and a higher proportion of shock at arrival at the medical center (P=.015) than the nonfatal subgroup. In group 2, the effect of a first- or secondgeneration cephalosporin plus an aminoglycoside was negative (P = .01) and that of combined third-generation cephalosporin and tetracycline or its analogue was positive (P

UR - http://www.scopus.com/inward/record.url?scp=33750355395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750355395&partnerID=8YFLogxK

U2 - 10.1001/archinte.166.19.2117

DO - 10.1001/archinte.166.19.2117

M3 - Article

VL - 166

SP - 2117

EP - 2123

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 19

ER -